Counterfeit Drugs
(1999; 61 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentExecutive Summary
Open this folder and view contents1. Introduction
View the document2. Overview of the problem
View the document3. Impact on public health
View the document4. Factors facilitating counterfeiting
Open this folder and view contents5. Developing national strategies
Open this folder and view contents6. Specific measures
Open this folder and view contents7. Assessment of the problem at the national level
Open this folder and view contents8. Inspection when pharmaceutical products are suspected to be counterfeit, spurious or substandard
Close this folder9. Test methods
View the document9.1 Methods based on thin-layer chromatography
View the document9.2 Other simple methods
View the document9.3 Analytical techniques
View the document9.4 Visual inspection
View the document9.5 Successful implementation of simple tests
Open this folder and view contents10. Developing training programmes: inspection and examination of counterfeit pharmaceuticals
View the document11. Conclusion
View the documentReferences
View the documentSelected further reading
View the documentAcknowledgements
View the documentGlossary
 

9.4 Visual inspection

Irrespective of the analytical method used, the first step in identifying potential counterfeit drugs is the careful visual inspection of the product, and its packaging and labelling. A comparison with the authentic drug product is always preferred. Differences in labelling, packaging and the physical appearance of dosage form, e.g. shape, colour, etc., indicate a potential counterfeit (8,9,24).

Even in the absence of knowledge of the physical characteristics of the authentic drug, a visual inspection may indicate that there has been tampering, that there is non-uniform colouration of the drug product under investigation, etc. Again such observations signal the possibility of a counterfeit.

Legitimate drug manufacturers should be encouraged to collaborate with national DRAs and with WHO by providing information and materials on the physical attributes of their products; this would be also be to their own benefit.

to previous section to next section
 

Last updated: May 3, 2013